Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22626306 | 0.94 | BCHE (0.30) | — | |
| SCHEMBL23489042 | 0.76 | BCHE (0.31) | — | |
| SCHEMBL19020690 | 0.73 | CHRM5 (0.39) | CHRM5ADRA2C | |
| SCHEMBL13551217 | 0.73 | CHRM5 (0.39) | CHRM5ADRA2C | |
| SCHEMBL21993005 | 0.69 | CHRM5 (0.37) | CHRM5ADRA2C | |
| SCHEMBL12738372 | 0.69 | CHRM5 (0.37) | CHRM5ADRA2C | |
| SCHEMBL21098358 | 0.67 | CHRM5 (0.43) | CHRM5ADRA2C | |
| SCHEMBL21575871 | 0.67 | DRD4 (0.45) | CHRM5ADRA2C | |
| SCHEMBL18844639 | 0.67 | CHRM5 (0.34) | CHRM5ADRA2C | |
| SCHEMBL23776218 | 0.67 | DRD4 (0.45) | CHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | CHRM5 4779/4885ADRA2C 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.